Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 88

Similar articles for PubMed (Select 20592273)

1.

An amyloid-notch hypothesis for Alzheimer's disease.

Ethell DW.

Neuroscientist. 2010 Dec;16(6):614-7. doi: 10.1177/1073858410366162. Epub 2010 Jun 30. Review.

PMID:
20592273
2.

γ-Secretase-regulated mechanisms similar to notch signaling may play a role in signaling events, including APP signaling, which leads to Alzheimer's disease.

Nakayama K, Nagase H, Koh CS, Ohkawara T.

Cell Mol Neurobiol. 2011 Aug;31(6):887-900. doi: 10.1007/s10571-011-9688-z. Epub 2011 Apr 23. Review.

PMID:
21516353
3.

Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.

Martone RL, Zhou H, Atchison K, Comery T, Xu JZ, Huang X, Gong X, Jin M, Kreft A, Harrison B, Mayer SC, Aschmies S, Gonzales C, Zaleska MM, Riddell DR, Wagner E, Lu P, Sun SC, Sonnenberg-Reines J, Oganesian A, Adkins K, Leach MW, Clarke DW, Huryn D, Abou-Gharbia M, Magolda R, Bard J, Frick G, Raje S, Forlow SB, Balliet C, Burczynski ME, Reinhart PH, Wan HI, Pangalos MN, Jacobsen JS.

J Pharmacol Exp Ther. 2009 Nov;331(2):598-608. doi: 10.1124/jpet.109.152975. Epub 2009 Aug 11.

4.
5.

The novel gamma secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse.

Best JD, Smith DW, Reilly MA, O'Donnell R, Lewis HD, Ellis S, Wilkie N, Rosahl TW, Laroque PA, Boussiquet-Leroux C, Churcher I, Atack JR, Harrison T, Shearman MS.

J Pharmacol Exp Ther. 2007 Feb;320(2):552-8. Epub 2006 Nov 10.

6.

Alzheimer's disease and Notch signaling.

Woo HN, Park JS, Gwon AR, Arumugam TV, Jo DG.

Biochem Biophys Res Commun. 2009 Dec 25;390(4):1093-7. doi: 10.1016/j.bbrc.2009.10.093. Epub 2009 Oct 22. Review.

PMID:
19853579
7.

Gamma-secretase inhibition reduces spine density in vivo via an amyloid precursor protein-dependent pathway.

Bittner T, Fuhrmann M, Burgold S, Jung CK, Volbracht C, Steiner H, Mitteregger G, Kretzschmar HA, Haass C, Herms J.

J Neurosci. 2009 Aug 19;29(33):10405-9. doi: 10.1523/JNEUROSCI.2288-09.2009.

8.

Identification of two novel synaptic γ-secretase associated proteins that affect amyloid β-peptide levels without altering Notch processing.

Frykman S, Teranishi Y, Hur JY, Sandebring A, Yamamoto NG, Ancarcrona M, Nishimura T, Winblad B, Bogdanovic N, Schedin-Weiss S, Kihara T, Tjernberg LO.

Neurochem Int. 2012 Jul;61(1):108-18. doi: 10.1016/j.neuint.2012.03.016. Epub 2012 Apr 10.

PMID:
22521230
10.

Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity.

Barten DM, Meredith JE Jr, Zaczek R, Houston JG, Albright CF.

Drugs R D. 2006;7(2):87-97. Review.

PMID:
16542055
11.

Alzheimer's disease: presenilin 2-sparing γ-secretase inhibition is a tolerable Aβ peptide-lowering strategy.

Borgegård T, Gustavsson S, Nilsson C, Parpal S, Klintenberg R, Berg AL, Rosqvist S, Serneels L, Svensson S, Olsson F, Jin S, Yan H, Wanngren J, Jureus A, Ridderstad-Wollberg A, Wollberg P, Stockling K, Karlström H, Malmberg A, Lund J, Arvidsson PI, De Strooper B, Lendahl U, Lundkvist J.

J Neurosci. 2012 Nov 28;32(48):17297-305. doi: 10.1523/JNEUROSCI.1451-12.2012.

12.

A GPCR/secretase complex regulates beta- and gamma-secretase specificity for Abeta production and contributes to AD pathogenesis.

Teng L, Zhao J, Wang F, Ma L, Pei G.

Cell Res. 2010 Feb;20(2):138-53. doi: 10.1038/cr.2010.3. Epub 2010 Jan 12.

PMID:
20066010
13.

Genes and mechanisms involved in beta-amyloid generation and Alzheimer's disease.

Steiner H, Capell A, Leimer U, Haass C.

Eur Arch Psychiatry Clin Neurosci. 1999;249(6):266-70. Review.

PMID:
10653281
14.

Catalytic site-directed gamma-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and beta-APP cleavages.

Lewis HD, Pérez Revuelta BI, Nadin A, Neduvelil JG, Harrison T, Pollack SJ, Shearman MS.

Biochemistry. 2003 Jun 24;42(24):7580-6.

PMID:
12809514
15.

Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice.

Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T.

Am J Pathol. 2007 Feb;170(2):680-92.

16.

Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor.

Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM.

J Pharmacol Exp Ther. 2005 Feb;312(2):635-43. Epub 2004 Sep 27.

17.

The gamma-secretase-generated intracellular domain of beta-amyloid precursor protein binds Numb and inhibits Notch signaling.

Roncarati R, Sestan N, Scheinfeld MH, Berechid BE, Lopez PA, Meucci O, McGlade JC, Rakic P, D'Adamio L.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):7102-7.

18.

gamma-Secretase as a therapeutic target in Alzheimer's disease.

Guardia-Laguarta C, Pera M, Lleó A.

Curr Drug Targets. 2010 Apr;11(4):506-17. Review.

PMID:
20015011
19.

APP, Notch, and presenilin: molecular pieces in the puzzle of Alzheimer's disease.

Wolfe MS.

Int Immunopharmacol. 2002 Dec;2(13-14):1919-29. Review.

PMID:
12489805
20.

Role of presenilin in gamma-secretase cleavage of amyloid precursor protein.

Xia W.

Exp Gerontol. 2000 Jul;35(4):453-60. Review.

PMID:
10959033
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk